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Background: 40 subjects with type 2 diabetes and moderate to severe CP were randomly distributed to groups
receiving either NSPT or OHI. Periodontal parameters, glycosylated haemoglobin (HbA1c) and high-sensitivity
C-reactive protein (hs-CRP) were evaluated at baseline, 2- and 3-months intervals.
Methods: 40 subjects with type 2 diabetes and moderate to severe CP were randomly distributed to groups
receiving either NSPT or OHI. Periodontal parameters, glycosylated haemoglobin (HbA1c) and high-sensitivity
C-reactive protein (hs-CRP) were evaluated at baseline, 2- and 3-months intervals.
Results: 15 subjects from NSPT group and 17 from OHI group completed the study. The difference in plaque index
(PI) between NSPT and OHI groups were significant at 2 months recall (p = 0.013). There was no significant
difference between NSPT and OHI group for all other clinical periodontal parameters, HbA1c and CRP levels. At 3
months post-therapy, periodontal parameters improved significantly in both groups with sites with probing pocket
depth (PPD) < 4 mm reported as 98 ± 1.8% in NSPT group and 92 ± 14.9% in OHI group. Mean PPD and mean
probing attachment loss (PAL) within the NSPT group reduced significantly from baseline (2.56 ± 0.57 mm, 3.35 ±
0.83 mm) to final visit (1.94 ± 0.26 mm, 2.92 ± 0.72 mm) (p = 0.003, p < 0.001). For OHI group, improvements in
mean PPD and mean PAL were also seen from baseline (2.29 ± 0.69 mm, 2.79 ± 0.96 mm) to final visit (2.09 ± 0.72
mm, 2.62 ± 0.97 mm) (p < 0.001 for both). Similarly, HbA1c levels decreased in both groups with NSPT group
recording statistically significant reduction (p = 0.038). Participants who demonstrated ≥ 50% reduction in PPD
showed significant reductions of HbA1c and hs-CRP levels (p = 0.004 and p = 0.012).
Conclusion: NSPT significantly reduced PI at 2 months post-therapy as compared to OHI. Both NSPT and OHI
demonstrated improvements in other clinical parameters as well as HbA1c and CRP levels.
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Periodontal diseases, such as periodontitis, are common
infections which if left untreated, can affect the tooth
supporting structures and ultimately lead to tooth loss.
The main etiological agent of periodontitis is considered
to be the dental biofilm [1]. However, multiple causal
factors like smoking/tobacco use [2], genetics [3], hor-
monal changes [4], stress [5], medications [6], diabetes
mellitus [7], poor nutrition [8] and systemic diseases [9]
that interfere with the body’s immune system play a
major role.
Chronic periodontitis has been implicated with several
disease processes in the body such as pre-eclampsia and
preterm births [10], cardiovascular events [11], respira-
tory disease [12], chronic renal disease [13], rheumatoid
arthritis [14] and diabetes mellitus [7]. Data obtained
from several studies strongly suggest diabetes as a risk
factor for gingivitis and chronic periodontitis [15]. Evi-
dence also suggests that periodontal changes are the first
clinical manifestation of diabetes [16].
Looking from the other perspective, increase in the se-
verity of chronic periodontitis was closely related to the
development of glucose intolerance [17]. It has been re-
ported that subjects with severe chronic periodontitis
and type 2 diabetes are 6 times more likely to have
poorer glycaemic control [18]. Longitudinal studies have
reported that infections of periodontal origin have an ad-
verse effect on glycaemic control [19]. A chronic state of
hyperglycaemia negatively affects neutrophil function
causing a dysfunctional inflammatory response and ham-
pering tissue repair. The concentration of advanced gly-
cation end-products (AGE) which can directly affect
normal protein function, or indirectly act by reacting
with RAGE (receptors for AGE) on the cell membrane
of a variety of cells is elevated in people with type 2 dia-
betes [20]. These glycated products alter the functional
properties of several important matrix molecules such as
type 1 collagen and laminin.
The American Academy of Periodontology treatment
guidelines [21] stress that periodontal health should be
achieved in the least invasive and most cost-effective
manner. This is often accomplished through non-
surgical periodontal treatment (NSPT), including oral
hygiene instructions (OHI), scaling and root planing of
the root surface to remove plaque, calculus and bacterial
toxins from deep periodontal pockets. Adjunctive ther-
apy, such as antimicrobial therapy and host modulation
are incorporated into the treatment regimen as required
on a case-by-case basis.
Intervention trials have suggested that there was an
improvement in glycaemic control in people with type 2
diabetes following non-surgical periodontal therapy [22].
However, a recent meta-analysis of intervention studies
suggests that more evidence is required to confirm theeffects of periodontal therapy on the metabolic control
of people with type 2 diabetes [23]. The aim of this study
was to determine the effect of NSPT as compared to
thorough OHI on the metabolic control as well as sys-
temic inflammatory marker, hs C-reactive protein (hs-
CRP), among a population of type 2 diabetes afflicted
with moderate to severe chronic periodontitis.Methods
Subjects
Ethical approval was obtained from both the Medical
Ethics Boards of University of Malaya Medical Centre
(MEC Ref No: 696.9) and University of Malaya Dental
Centre [DF PE1002/0045(P)]. The study was conducted
in accordance with the Helsinki Declaration of 1975, as
revised in 2000. The CONSORT guidelines for clinical
trials were followed. The Clinical Trials.gov registration
number for this study is NCT01951547.
One hundred and twelve people with type 2 diabetes
(diagnosed at least 1 year prior to the study) between
ages of 30 to 70 were screened from the outpatient Dia-
betes Clinic of the University of Malaya Medical Centre
and a total of 40 subjects who fulfilled the inclusion and
exclusion criteria were recruited for the study. The re-
cruited subjects were then registered at the Periodontol-
ogy Clinic at the Faculty of Dentistry, University of
Malaya. Patient information sheets regarding the study
and verbal explanations were given to all subjects. Writ-
ten informed consent was obtained from all recruited
subjects with the understanding that they could with-
draw from the study at any time. Inclusion criteria were:
presence of moderate to advanced chronic periodontitis
[24], with at least 12 teeth present and with 5 or more
pockets of 5 mm or more and probing attachment loss
of 4 mm or more in at least 2 different quadrants which
bled on probing. Exclusion criteria included: a history of
systemic antibiotic usage over the previous 4 months,
having received non-surgical periodontal treatment
within the past 6 months or surgical periodontal treat-
ment within the past 12 months; pregnancy, change of
medication for diabetes during the course of the study,
current smokers or history of a cerebrovascular or car-
diovascular event within the past 12 months.Sample size calculation
The sample size calculation determined that 15 subjects
per treatment arm would provide 80% power to detect a
minimum difference of 1% (11.0 mmol/mol) change in
HbA1c between test and control [25]. Accordingly, a
sample of 20 subjects per arm (40 in total) was recruited
to compensate for possible drop-outs during the study
period. All subjects were assigned via block randomisa-
tion to age matched NSPT and OHI groups [26].
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and HbA1c were obtained.
Examiner calibration
As there was only one examiner involved in the study,
intra-examiner reliability assessment was executed. This
was done to validate the ability of the examiner to con-
stantly reproduce the quantitative outcome measure-
ments of the clinical parameters used. The Plaque Index
(PI) [27], Gingival Bleeding Index (GBI) [27], Probing
Pocket Depth (PPD) and Probing Attachment Loss (PAL)
were measured in the time interval of about 3 hours. Utiliz-
ing Kappa statistics, good agreements (>0.8) were obtained
for reproducibility of all recorded clinical parameters.
Periodontal examination
All recruited subjects underwent full periodontal assess-
ment at baseline, 2 months after assigned treatment and
3 months after assigned treatment. The clinical examin-
ation included Plaque Index (PI), Gingival Bleeding
Index (GBI), Probing Pocket Depth (PPD) and Probing
Attachment Loss (PAL) measured with an electronic
constant- force probe (Florida Probe®). PPD was mea-
sured with the gingival margin as the reference point
and PAL was measured with the cement-enamel junc-
tion as reference. The trial design and the timing of clin-
ical interventions and sampling are summarized in
Figure 1.
Periodontal intervention
All subjects were instructed in oral hygiene methods
using a soft bristled toothbrush, a compact-tuft tooth-
brush, interdental brushes and dental floss (TePe® oral
hygiene education set) utilizing the modified Bass tech-
nique. Plaque scores of the subjects in the NSPT group
were reviewed at weekly intervals to achieve scores of
20% or below to a maximum of 3 weeks. Subjects were
re-motivated and instructed when necessary. Assigned
treatment for the NSPT group was full mouth debride-
ment, which consisted of scaling and root planing, was
done in a single visit for all subjects in the NSPT group
using an ultrasonic scaler (SATELEC P5 Newtron XS,
Acteon, Merignac, France) and Gracey curretes (Hu-
Friedy, Chicago, USA). Additionally, all subjects in the
NSPT group were given a 0.12% Chlorhexidine mou-
thrinse (Hexipro®, Evapharm, Kuala Lumpur, Malaysia).
They were instructed to rinse three times a day using
15 ml each time for a period of 14 days commencing im-
mediately after completion of full mouth debridement.
No interventional treatment was given to the OHI group
apart from oral hygiene instructions and motivation.
Thereafter at each monthly recall visit, participants in
both groups were reviewed and re-motivated. Professionalprophylaxis comprising of scaling and polishing was per-
formed only on subjects of the test group.
Measurement of glycated haemoglobin and hs-CRP
15 ml of venous blood was collected from each patient
at baseline, prior to treatment and at 3 months after
assigned treatments. Levels of glycosylated haemoglobin
(HbA1c) and systemic hs-CRP were assessed. Hs-CRP
levels were assessed using tests for High sensitivity CRP
(hs-CRP). All blood investigations were done at a private
laboratory (Gnosis Laboratories Sdn. Bhd) with no affili-
ation to the Department of Periodontology. The HbA1c
testing is DCCT aligned and the Quality Assurance of
the laboratory is certified under Bio-Rad Laboratories
(USA), EQAS (External Quality Assurance Services).
Statistical analysis
Comparisons of changes in PI, GBI, PPD (%) and PAL
(%) both within and between the groups were performed
using the chi-square test. Intragroup comparison for
mean PPD, mean PAL, mean HbA1c and mean CRP
were assessed with the paired sample t-test whereas in-
tergroup comparisons for the same variables was accom-
plished using an independent sample t-test.
Results
Screening and treatment of subjects commenced from
May 2010 till April 2011. 15 subjects completed the
study protocol in the NSPT group (n = 15) and 17 in the
OHI group (n = 17). This gave a within group analyses
power of 80% for the NSPT group and 88% for the OHI
group. 2 of the 5 subjects from the NSPT group who did
not complete the study had their diabetic medication
changed during the course of the study and had to be
excluded. 2 out of the remaining 3 chose to withdraw
from the study for unspecified reasons and the last one
was unable to attend recall visits as she was living quite
a distance away and was unable to secure transport to
the faculty. For the OHI group, 1 subject had his medi-
cations for Type 2 diabetes changed and the remaining 2
withdrew consent after the 2 months recall visit for un-
specified reasons. Despite the dropouts, the remaining
number of subjects in the NSPT and OHI groups was
enough to show a power of study of 80%.
At baseline, there was no significant difference be-
tween the NSPT and OHI group in terms of age, gender,
ethnicity (Table 1) and distribution of periodontal pa-
rameters (Tables 2 and 3). All subjects who completed
the study were on oral hypoglycaemic drugs.
Periodontal parameters
Changes in PI and GBI from baseline to the recall visit
(2 months) and to the final visit (3 months) are shown
in Table 2. The difference in PI scores between NSPT
Figure 1 Flow chart of the Study Protocol. Flow chart shows the recruitment of subjects and baseline randomization of subjects into the NSPT
or OHI groups. Following intervention, subjects are reviewed up to 3 months post-therapy. (OHI: oral hygiene instructions; NSPT: nonsurgical
periodontal therapy).
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(p = 0.013) but by the final visit the difference was no
longer significant (p > 0.05). At all time points there were
no significant difference in GBI scores between NSPT and
OHI groups (p > 0.05).
The reduction in PI scores within the NSPT group from
baseline to 2 months recall and final visit were statistically
significant (p < 0.001) and the large effect sizes indicated a
significant clinical improvement. The reduction in PI seen
within the OHI group was also statistically significant(p < 0.001) at all time points. GBI scores for the NSPT
group improved from 21% at baseline to 3% at 2 months
recall (p = 0.006) and 1.2% at 3 months recall (p = 0.003).
For the OHI group, there was an improvement in GBI
score from 22% at baseline to 6.4% at recall (p < 0.001).
However, at the final visit, the GBI increased 2.5 times,
and the change from baseline values were no longer statis-
tically significant (p = 0.466).
At all time points there were no significant difference
in mean PPD and mean PAL between NSPT and OHI
Table 1 Sociodemographic data of study sample
Variable NSPT group (n = 15) OHI group (n = 17) p-value
Age (years) (mean ± SD) 57.7 ± 9.9 54.6 ± 6.2 0.28
Ethnicity
Malay 5 (33.3%) 4 (23.5%) 0.75
Chinese 4 (26.7%) 4 (23.5%)
Indian 6 (40.0%) 9 (52.9%)
Gender
Male 11 (73.3%) 9 (52.9%) 0.23
Female 4 (26.7%) 8 (47.1%)
Duration of diabetes
< 7 years 4 (26.7%) 3 (17.6%) 0.76
7-12 years 4 (26.7%) 4 (23.5%)
> 12 years 7 (46.7%) 10 (58.8%)
p-value - independent sample t-test used for age.
-chi-square test used for ethnicity, gender and duration of diabetes.
Table 2 Comparison of plaque index and gingival bleeding index at baseline, 2 months and 3 months between NSPT
and OHI group
NSPT group (n = 15) (% ± SD) OHI group ( n = 17) (% ± SD) p-value
Plaque index
Baseline 40.06 ± 22.44 32.70 ± 21.08 0.346
2 months 4.65 ± 4.63 12.06 ± 10.01 0.013*
3 months 1.96 ± 5.97 4.88 ± 5.88 0.174
P1 value <0.001* <0.001*
P2 value <0.001* <0.001*
P3 value 0.157 <0.001*
Effect Size1 1.747 1.480
Effect Size2 1.704 1.577
Effect Size3 0.386 1.193
Gingival bleeding index
Baseline 20.81 ± 21.07 21.56 ± 15.22 0.908
2 months 2.97 ± 3.98 6.40 ± 10.00 0.224
3 months 1.18 ± 1.66 14.85 ± 46.32 0.263
P1 value 0.006* <0.001*
P2 value 0.003* 0.565
P3 value 0.092 0.466
Effect Size1 0.844 2.108
Effect Size2 0.942 0.143
Effect Size3 0.467 0.181
*p < 0.05 ( statistically significant).
p1 - p-value of baseline compared to 2 months.
p2 - p-value of baseline compared to 3 months.
p3 - p-value of 2 months compared to 3 months.
Effect Size1 - effect size of baseline compared to 2 months.
Effect Size2 – effect size of baseline compared to 3 months.
Effect Size3 – effect size of 2 months compared to 3 months.
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Table 3 Comparison of probing pocket depths and probing attachment loss at baseline, 2 months and 3 months
between NSPT and OHI group
NSPT group (n = 15) OHI group ( n = 17) *p †p
Sites with PPD
< 4 mm (% ± SD)
Sites with PAL
< 4 mm (% ± SD)
Sites with PPD
< 4 mm (% ± SD)
Sites PAL
< 4 mm (% ± SD)
Baseline 81.14 ± 13.38 63.45 ± 21.29 87.54 ± 15.00 75.98 ± 20.37 0.215 0.099
2 months 95.61 ± 3.50 71.60 ± 19.26 90.32 ± 15.29 78.99 ± 21.17 0.138 0.312
3 month 97.96 ± 1.75 74.93 ± 18.03 91.67 ± 14.86 80.10 ± 21.57 0.633 0.472
P1 value <0.001* <0.001* 0.001* <0.001*
P2 value <0.001* <0.001* <0.001* <0.001*
P3 value 0.008* 0.002* 0.001* 0.005*
Effect Size1 1.205 0.822 0.991 0.792
Effect Size2 1.289 0.982 1.383 0.928
Effect size3 0.794 0.994 0.962 0.786
Sites with PPD Sites with PAL Sites with PPD Sites with PAL
4-6 mm (% ± SD) 4-6 mm (% ± SD) 4-6 mm (% ± SD) 4-6 mm (% ± SD)
Baseline 16.51 ± 10.97 28.62 ± 16.19 11.00 ± 9.52 19.59 ± 12.06 0.201 0.082
2 months 4.28 ± 3.53 23.69 ± 16.84 8.54 ± 10.87 17.55 ± 13.72 0.158 0.264
3 month 2.04 ± 1.75 21.40 ± 16.06 7.31 ± 10.85 16.63 ± 14.44 0.381 0.384
P1 value <0.001* <0.001* 0.005* <0.001*
P2 value <0.001* <0.001* <0.001* <0.001*
P3 value 0.012* 0.013* 0.002* 0.032*
Effect Size1 1.303 0.624 0.797 0.516
Effect Size2 1.371 0.769 1.127 0.619
Effect Size3 0.749 0.733 0.900 0.570
Sites with PPD Sites with PAL Sites with PPD Sites with PAL
>6 mm (% ± SD) >6 mm (% ± SD) >6 mm (% ± SD) >6 mm (% ± SD)
Baseline 2.36 ± 3.14 7.93 ± 7.87 1.54 ± 5.80 4.29 ± 9.77 0.115 0.260
2 months 0.06 ± 0.23 4.55 ± 4.64 1.14 ± 4.69 3.40 ± 8.91 0.074 0.656
3 month 0.00 ± 0.00 3.67 ± 4.06 1.02 ± 4.20 3.27 ± 8.40 0.356 0.869
P1 value 0.012* 0.001* 0.168 <0.001*
P2 value 0.012* 0.001* 0.203 <0.001*
P3 value 0.334 0.011* 0.332 0.407
Effect Size1 0.747 0.655 0.350 0.757
Effect Size2 0.749 0.803 0.322 0.612
Effect Size3 0.258 0.751 0.243 0.207
Mean PPD (mean ± SD) Mean PAL (mean ± SD) Mean PPD (mean ± SD) Mean PAL (mean ± SD)
Baseline 2.56 ± 0.57 3.35 ± 0.83 2.29 ± 0.69 2.79 ± 0.96 0.535 0.089
2 months 1.94 ± 0.26 2.92 ± 0.72 2.09 ± 0.72 2.62 ± 0.97 0.459 0.329
3 months 1.76 ± 0.19 2.73 ± 0.70 2.02 ± 0.71 2.56 ± 0.97 0.179 0.560
P1 value 0.004* <0.001* <0.001* <0.001*
P2 value 0.003* <0.001* <0.001* <0.001*
P3 value <0.001* <0.001* 0.001* 0.002*
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Table 3 Comparison of probing pocket depths and probing attachment loss at baseline, 2 months and 3 months
between NSPT and OHI group (Continued)
Effect Size1 0.873 1.893 1.090 1.396
Effect Size2 2.057 2.057 1.528 1.528
Effect Size3 1.506 1.697 0.967 1.282
*p - intergroup p-value for PPD.
†p - intergroup p-value for PAL.
p1 - p-value of baseline compared to 2 months (*p < 0.05 - statistically significant).
p2 - p-value of baseline compared to 3 months (*p < 0.05 - statistically significant).
p3 – p-value of 2 months compared to 3 months (*p < 0.05 -statistically significant).
Effect Size1 - effect size of baseline compared to 2 months.
Effect Size2 – effect size of baseline compared to 3 months.
Effect Size3 – effect size of 2 months compared to 3 months.
Table 4 Characteristics of monitored systemic markers at
baseline and 3 months after treatment
NSPT group (n = 15) OHI group (n = 17) p-value
HbA1c
% ± SD
(mmol/mol ± SD)
Baseline 7.8 ± 1.5 (61 ± 12) 7.6 ± 1.5 (60 ± 11) 0.791
3 months 7.1 ± 1.2 (54 ± 9) 7.1 ± 1.2 (54 ± 9) 0.995
P value 0.038* 0.053
Effect Size 0.593 0.495
hs-CRP
Baseline 10.5 ± 15.8 5.6 ± 5.2 0.238
3 months 7.0 ± 13.4 5.6 ± 5.3 0.687
P value 0.076 0.783
Effect size 0.506 0.068
*p <0.05 ( statistically significant).
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NSPT group reduced significantly from 6 mm at baseline
to 2 mm at recall (p = 0.004) and < 2 mm at the final visit
(p = 0.003). The reduction from recall to the final visit
was also significant (p < 0.001). In the OHI group, the
mean PPD reduced by > 50% at recall (p < 0.001) and re-
duced further at the final visit (p < 0.001). However be-
tween the recall and final visits, the intragroup reductions
seen, although significant, were less than the NSPT group.
Effect sizes within both groups were large at all time pe-
riods, indicating significant clinical changes.
The mean PAL for NSPT group reduced from 3.35 mm
at baseline to 2.73 mm at the final visit (Table 3). The
changes between all time periods were statistically signifi-
cant (p < 0.001). In the OHI group, the mean PAL im-
proved from 2.79 mm at baseline to 2.56 mm at the final
visit. The changes from baseline to recall and to the final
visit were also statistically significant (p < 0.001). The ef-
fect size in both groups recorded a considerable improve-
ment in mean PAL during the course of the study.
Overall, there were more sites of PPD and PAL of <4 mm
at the end of the study and fewer sites with PPD and PAL
of > 6 mm.
Serum HbA1c and CRP levels
At baseline and final visit, HbA1c and CRP levels be-
tween NSPT and OHI subjects were not significantly dif-
ferent (p > 0.05) (Table 4). However, within the NSPT
group, there was a statistically significant reduction in
levels of HbA1c from baseline to final visit (p = 0.038)
which was not seen in the OHI group (p = 0.053). For
serum CRP levels, the mean value at baseline for the
NSPT group was almost twice as high compared to the
OHI group but not statistically significant (Table 4). The
reductions observed within both the NSPT and OHI
groups at the final visit did not reach statistical signifi-
cance (p > 0.05). However for CRP reduction in the
NSPT group, the effect size was moderate which indi-
cated that the improvement was of clinical significance.
For the OHI group, the mean CRP at baseline and at the
final visit was almost similar.Changes in serum HbA1c and CRP levels for subjects with
good periodontal response to treatment
Out of the total sample population, following either
NSPT or OHI intervention, participants with a plaque
score reduction of ≥ 50% recorded a clinically signifi-
cant reduction in HbA1c as indicated by the effect size
(ES = 0.853) but no significant changes in hs-CRP levels
(Table 5). For those participants with a ≥ 50% reduction
in gingival bleeding sites, neither HbA1c nor hs-CRP
reached statistical significance (p = 0.205 and p = 0.289)
but both had large effect sizes (ES = 2.121 and ES = 1.452
respectively), indicating a clinically significant reduction.
Out of the total sample population (n = 32), 16 partici-
pants demonstrated a ≥ 50% reduction in PPD as an
effect of periodontal intervention, be it just OHI or
NSPT. These participants also demonstrated a statistically
significant reduction in HbA1c (p = 0.004) and hs-CRP
(p = 0.012) levels.
Discussion
The results of this study demonstrate that in the man-
agement of Type 2 diabetic subjects with chronic peri-
odontitis, other than a significant reduction in PI at
Table 5 Changes in mean HbA1c and CRP for subjects with good response to periodontal treatment in OHI and NSPT
groups
Reduction of periodontal
parameters after treatment
Baseline 3 months p-value Effect size
(ES)
HbA1c hs-CRP HbA1c hs-CRP p1 p2 ES1 ES2
(mean ± SD mmol/mol ± SD) (mean ± SD) (mean ± SDmmol/mol ± SD) (mean ± SD)
Subjects with a 50% reduction
in plaque index scores (n = 7)
8.2 ± 1.1 66 ± 9 5.3 ± 3.6 7.1 ± 1.6 57 ± 12 4.9 ± 3.6 0.065 0.666 0.853 0.171
Subjects with a 50% reduction
in gingival bleeding scores (n = 2)
9.0 ± 0.3 75 ± 2 10.0 ± 0.4 7.7 ± 0.4 60 ± 3 8.1 ± 0.9 0.205 0.289 2.121 1.452
Subjects with a 50% reduction
in mean PPD (n = 16)
7.7 ± 1.4 60 ± 11 9.6 ± 14.6 6.8 ± 0.8 51 ± 6 8.2 ± 12.9 0.004 0.012 0.859 0.710
p1 - p value of HbA1c between baseline and 3 months.
p2 - p values of hs-CRP between baseline and 3 months.
ES1 - effect size of HbA1c from baseline to 3 months.
ES2 - effect size of hs-CRP from baseline to 3 months.
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ence in all clinical periodontal parameters, HbA1c and
CRP levels when comparing NSPT and OHI. The signifi-
cant difference in the PI score at 2 months post-therapy
could be due to the repeated professional debridement
provided as well as the absence of plaque retentive fac-
tors in the NSPT group which made plaque control eas-
ier and reduced inflammation.
The data also showed clinically significant improve-
ment in periodontal parameters within both groups.
Other studies have reported similar findings with the
greatest improvements seen in the intervention of test
groups [28,29]. Lalla and co-workers [30] recorded a
50% reduction of clinical parameters from baseline. Evi-
dence has always indicated that non-surgical periodontal
treatment is the gold standard of periodontal treatment
and the results of this study concur. The mere act of
proper plaque removal in the OHI group also led to a
significant degree of disease resolution, albeit not as
quickly or as extensive as seen in the NSPT group. Two
prior studies have corroborated this finding with im-
provements in the plaque index (by as much as 47%) as
well as significant reductions in the gingival bleeding
index [31,32]. At 3 months post therapy, there was how-
ever significant variability in the standard deviation seen
for the plaque index in the NSPT group and the gingival
bleeding index in the OHI group and this may have been
due to the variability in the response to treatment for
both groups.
In this study, there was no difference in the improve-
ment in HbA1c levels between NSPT and OHI groups.
However, the data indicates that NSPT resulted in a sig-
nificant improvement in glycaemic control. The NSPT
group showed a mean reduction in HbA1c of 0.7%
(8 mmol/mol) (p < 0.05) and the OHI group showed a
reduction of 0.5% (6 mmol/mol) (p > 0.05). The reduc-
tion in HbA1c levels for the NSPT group concur with
findings by Darre and colleagues [33] who reported areduction of 0.8% (9 mmol/mol) following periodontal
therapy. Other researchers have also reported the same
phenomena [22,34]. HbA1c reductions as high as 17.1%
have also been reported [22]. Recently, the team at the
Joint EFP/AAP Workshop on Periodontitis and Systemic
Diseases published a consensus report stating over-
whelming evidence on the effect of periodontal interven-
tion on glycaemic control. Randomized controlled trials
(RCTs) consistently demonstrated that mechanical peri-
odontal therapy associates with approximately a 0.4%
reduction in HbA1C at 3 months, a clinical impact
equivalent to adding a second drug to a pharmacological
regime for diabetes [35]. This further affirms the find-
ings of this study as well as those by Sgolastra and col-
leagues [36] who conducted a meta-analysis on randomized
clinical trials on the effect of periodontal treatment on
metabolic control. They reported that NSPT was effective
at reducing HbA1c and fasting plasma glucose. It is inter-
esting to note that the control group which received OHI
alone also demonstrated reductions in their HbA1c levels
(p = 0.053, ES = 0.495). Teaching diabetics the proper
method of plaque control and correcting improper brush-
ing techniques was able to translate into a clinically relevant
improvement in metabolic control.
Both NSPT and OHI demonstrated similar improve-
ments in CRP levels. Improvements in mean levels of
hs-CRP in both NSPT and OHI groups did not reach
statistical significance. The lack of a statistical signifi-
cance should be taken with caution as this may be at-
tributed to the small sample size rather than the true
difference. Changes in hs-CRP levels were moderate at
best and this could be due to the non-specific nature of
this inflammatory marker. Reports in the literature have
been contradictory [30,37,38]. It has been noted that the
reduction in serum hs-CRP was greater in treatment
regimens that combine systemic or local antibiotics with
standard periodontal treatment [37]. Since no antibiotics
were used in this study, it may explain the lack of an
Raman et al. BMC Oral Health 2014, 14:79 Page 9 of 10
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ation is that during the randomization of subjects, more
participants with poor metabolic control were placed in
the NSPT group. In the OHI group, there was equal dis-
tribution of participants with poor and good metabolic
control. Thus the mean CRP levels at baseline were al-
most 2 fold higher in the NSPT group (10.51) as com-
pared to OHI subjects (5.64). However, at 3 months after
treatment, more participants were categorized as well con-
trolled diabetics in both groups. It is important to note
that the present data does indicate that participants who
responded well to periodontal therapy also recorded clin-
ically relevant reductions in levels of HbA1c and hs-CRP.
Results of this study show that participants who re-
corded clinically significant improvements in the PI, GBI
and PPD also showed concurrent improvement in
HbA1c levels. Clinically relevant reductions in CRP
levels were also seen in participants with improvements
in gingival bleeding scores and PPD. Good periodontal
response to interventional periodontal therapy (NSPT or
OHI) is mirrored by improvements in metabolic control
and reductions in the on-going inflammatory challenge
in the body. These results were not in agreement with a
study by Llambes et al. [39], who reported no concurrent
statistically significant improvements in levels of HbA1c
when participants with good periodontal response to
treatment were analysed. At the end of the study proto-
col, there were 16 participants with more than 50%
reduction in PPD scores together with statistically
significant reduction in HbA1c (p = 0.004) and hs-CRP
(p = 0.012) levels. This clearly indicates that re-establishing
good periodontal health in type 2 diabetics with periodon-
tal disease has the potential of greatly improving metabolic
control and systemic inflammatory challenge. To date, no
other study has reported results in this associative manner.
However, these findings should be taken with caution as
the treatment modalities provided to bring about these im-
provements come from 2 different intervention methods.
A future study with a much larger sample size should be
conducted to look at the improvements in periodontal pa-
rameters from each intervention method and its effect in
improving metabolic control and systemic inflammatory
challenge.
The findings from this study show that both NSPT
and OHI were able to bring about similar improvements
in clinical periodontal parameters as well as HbA1c and
CRP levels. Rendering OHI does not require a dental
chair or any specific settings, with the right teaching
aids it can be taught to anyone. Routine assessment of
periodontal health in type 2 diabetes subjects should be
performed, and if disease is present, appropriate peri-
odontal management should thus be considered to im-
prove metabolic control and systemic inflammatory
challenge. One of the limitations of this study is thatthis randomized clinical trial was not double-blinded.
Due to ethical restrictions, we were unable to have a
control group without intervention. A future study
which includes double blinding and a much larger sam-
ple size would be able to evaluate the potential moderat-
ing roles of ethnicity and body weight on metabolic
control of these subjects. Also, the moderating role of
the chlorhexidine mouthwash needs to be considered,
with the inclusion of more study groups that exclude/in-
clude the use of the mouthwash.
Conclusion
NSPT significantly reduced PI scores at 2 months post-
therapy as compared to OHI. Both NSPT and OHI demon-
strated similar improvements in other clinical parameters
as well as HbA1c and CRP levels. Participants who dem-
onstrated ≥ 50% reduction in PPD following either OHI or
NSPT, presented with significant reduction in HbA1c and
hs-CRP levels.
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